Gilead Sciences stock: Raised outlook meets Denver liver-data focus
Published on 11/04/2026 at 17:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOutlook, pipeline and market focus
- Gilead raised its 2026 product-sales outlook after strong third-quarter demand.
- The company will present 21 liver-disease abstracts in Denver from November 5 to 9.
- HIV, oncology and liver medicines remain central to the growth outlook.
Gilead Sciences raised its full-year 2026 product-sales outlook on October 29 after reporting stronger third-quarter demand, while a major liver-disease conference is set to provide the next pipeline readout. At 17:11 CET on Wednesday, November 4, Gilead Sciences stock traded at 153.47 euros on Lang & Schwarz, 0.90 percent above the Xetra close of Tuesday, November 3 at 152.10 euros.
The company now expects 2026 product sales of 31.0 billion to 31.3 billion US dollars, compared with its previous range of 30.1 billion to 30.4 billion US dollars. Product sales excluding Veklury are forecast at 30.7 billion to 31.0 billion US dollars, versus 29.8 billion to 30.1 billion previously.
Third-quarter demand lifts guidance
In its third-quarter results release, Gilead said product sales excluding Veklury rose 16 percent year over year to 8.2 billion US dollars. HIV sales increased 18 percent to 6.2 billion US dollars, while Biktarvy sales gained 10 percent to 4.1 billion US dollars. Trodelvy sales rose 42 percent to 506 million US dollars.
The liver-disease portfolio grew 13 percent to 927 million US dollars, primarily reflecting higher demand for Livdelzi. The company also reported non-GAAP diluted earnings of 2.55 US dollars per share, compared with 2.47 US dollars a year earlier. Investors should distinguish this adjusted measure from GAAP diluted earnings of 1.94 US dollars per share.
Denver brings the next pipeline test
Gilead will present 21 accepted abstracts at The Liver Meeting 2026 in Denver from November 5 to 9, according to the company's conference announcement. The program includes late-breaking Phase 3 data for Livdelzi in primary biliary cholangitis and long-term and real-world evidence for Hepcludex in chronic hepatitis delta.
The event gives investors a near-term opportunity to assess progress beyond Gilead's core HIV franchise. The commercial outlook remains supported by HIV and oncology demand, but acquired research and development charges are weighing on reported full-year earnings guidance.
For the complete market snapshot, see the real-time quote of Gilead Sciences stock.
US equities remain focused on developments across the S&P 500, which provides the broader market backdrop for Gilead Sciences stock.
More news and analyses on Gilead Sciences stock are available on the company topic page.
Gilead Sciences stock at a glance
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Home exchange: Nasdaq
- Lang & Schwarz quote: 153.47 euros at 17:11 CET on Wednesday, November 4, 2026
- Change versus Xetra close: 0.90 percent above 152.10 euros on Tuesday, November 3, 2026
